EZZ has signed a regional sponsorship deal with the Australian Open. Pic: Getty images.
Health & Biotech
Special Report: EZZ Life Science Holdings has served up a three-year regional sponsorship deal with the Australian Open commencing in 2025, expanding its presence in key markets of China and Southeast Asia and targeting more than 330 million tennis fans.
Genomic life science company EZZ Life Science Holdings Limited (ASX:EZZ) said, as an official regional partner, EZZ will leverage the prestigious global sporting event to position the brand and expand its reach in China and Southeast Asia.
EZZ Life Science Chairman Glenn Cross said the deal will help the company build its presence across the region.
“China is home to more than 330 million tennis fans,” he said.
“Many of them follow the Australian Open, so we will create content tailored specifically for audiences across China with strategic initiatives designed to drive consumer engagement and boost brand awareness.”
Cross said EZZ would be offering a prize package including a trip for two to the Australian Open as well as hosting a series of product giveaways and promotional activities aligned with the Open.
“There will be curated content combining digital advertising on AO platforms, social media takeovers, and influencer collaboration for other key markets like Indonesia, the Philippines, Thailand and Vietnam, which are home to 550 million people, representing enormous additional potential for us to reach new audiences,” Cross said.
“These efforts are aimed at enhancing direct consumer interaction and driving product sales, reinforcing EZZ’s commitment to connecting with its customer base and expanding market presence.
“This campaign, backed by extensive digital advertising and social media engagement, is designed to deliver memorable experiences that connect consumers with EZZ’s mission of improving lives through cutting-edge health solutions.”
EZZ designs and distributes a range of consumer health products under the EZZ brand. The company focuses on genomic research and development to address four key human health challenges including genetic longevity, human papillomavirus (HPV), children’s care, and weight management.
The company is also the exclusive wholesale distributor for the EAORON branded skin care range to pharmacies, supermarkets and specialist retailers in Australia and New Zealand.
EZZ in August released its unaudited financial results for FY24 with record revenue of $66.4m, up 78.9% on the previous corresponding period.
“Our partnership with the Australian Open represents a significant step in our global expansion, particularly in our core markets of China and Southeast Asia,” he said.
“By aligning our brand with one of the world’s most celebrated sporting events, we aim to engage millions of consumers who share our passion for health, wellness, and innovation.”
This article was developed in collaboration with EZZ Life Sciences, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
